| |
|
|
|
|
|
|
|||
|
Blood, 1 January 2009, Vol. 113, No. 1, pp. 233-243. Prepublished online as a Blood First Edition Paper on October 2, 2008; DOI 10.1182/blood-2008-06-162891.
VASCULAR BIOLOGY Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCβ2 axis1 Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul; 2 Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Seoul; 3 Department of Radiology, Institute for Radiological Imaging Science, School of Medicine, Wonkwang University, Iksan; 4 Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon; 5 Department of Life Science, Division of Molecular and Life Science, Pohang University of Science and Technology, Pohang; 6 Laboratory of Stem Cell and Tumor Biology, College of Veterinary Medicine, Seoul National University, Seoul; 7 Department of Anatomy, College of Medicine, Hallym University, Gangwon-do; and 8 Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Kangwon-Do, Korea Homing of endothelial progenitor cells (EPCs) to the neovascular zone is now considered to be an essential step in the formation of vascular networks during embryonic development and also for neovascularization in postnatal life. We report here the prominent role of the insulin-like growth factor 2 (IGF2)/IGF2 receptor (IGF2R) system in promoting EPC homing. With high-level expression of IGF2R in EPCs, IGF2-induced hypoxic conditions stimulated multiple steps of EPC homing in vitro and promoted both EPC recruitment and incorporation into the neovascular area, resulting in enhanced angiogenesis in vivo. Remarkably, all IGF2 actions were exerted predominantly through IGF2R-linked G(i) protein signaling and required intracellular Ca2+ mobilization induced by the β2 isoform of phospholipase C. Together, these findings indicate that locally generated IGF2 at either ischemic or tumor sites may contribute to postnatal vasculogenesis by augmenting the recruitment of EPCs. The utilization of the IGF2/IGF2R system may therefore be useful for the development of novel means to treat angiogenesis-dependent diseases.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||